Among these, the AP-BEV + M1A-EXO formulation demonstrated superior efficacy, achieving a 65.4% reduction in tumor volume and significant decreases in tumor biomarkers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9), highlighting its potential as a precise and effective therapeutic strategy for CRC [164]. This evidence concerns the gene CEACAM5 and neoplasm.